American Journal of Cancer

, Volume 3, Supplement 2, pp 3–5 | Cite as

Review Article

Traitement adjusvant: bénéfice confirmé pour la chimiothérapie adjuvante à base de cisplatine dans les caners bronchiques opérés


  1. 1.
    Carbone DP, Minna JD. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 889–90PubMedCrossRefGoogle Scholar
  2. 2.
    Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352: 257–63Google Scholar
  3. 3.
    Keller SM, Adak S, Wagner H, et al. A randomised trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000; 343: 1217–22PubMedCrossRefGoogle Scholar
  4. 4.
    Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003; 95: 1453–61PubMedCrossRefGoogle Scholar
  5. 5.
    The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351–60CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Institut Gustave RoussyVillejuifFrance
  2. 2.Département de MédecineInstitut Gustave RoussyVillejuifFrance

Personalised recommendations